NUTX Relative Valuation
NUTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NUTX is overvalued; if below, it's undervalued.
Historical Valuation
Nutex Health Inc (NUTX) is now in the Fair zone, suggesting that its current forward PS ratio of 1.02 is considered Fairly compared with the five-year average of -23.37. The fair price of Nutex Health Inc (NUTX) is between 127.09 to 198.26 according to relative valuation methord.
Relative Value
Fair Zone
127.09-198.26
Current Price：178.09
Fair
8.47
PE
1Y
3Y
5Y
3.97
EV/EBITDA
Nutex Health Inc. (NUTX) has a current EV/EBITDA of 3.97. The 5-year average EV/EBITDA is 60.18. The thresholds are as follows: Strongly Undervalued below -157.38, Undervalued between -157.38 and -48.60, Fairly Valued between 168.96 and -48.60, Overvalued between 168.96 and 277.75, and Strongly Overvalued above 277.75. The current Forward EV/EBITDA of 3.97 falls within the Historic Trend Line -Fairly Valued range.
3.34
EV/EBIT
Nutex Health Inc. (NUTX) has a current EV/EBIT of 3.34. The 5-year average EV/EBIT is 109.35. The thresholds are as follows: Strongly Undervalued below -1101.18, Undervalued between -1101.18 and -495.92, Fairly Valued between 714.62 and -495.92, Overvalued between 714.62 and 1319.89, and Strongly Overvalued above 1319.89. The current Forward EV/EBIT of 3.34 falls within the Historic Trend Line -Fairly Valued range.
1.02
PS
Nutex Health Inc. (NUTX) has a current PS of 1.02. The 5-year average PS is 3.06. The thresholds are as follows: Strongly Undervalued below -11.32, Undervalued between -11.32 and -4.13, Fairly Valued between 10.25 and -4.13, Overvalued between 10.25 and 17.44, and Strongly Overvalued above 17.44. The current Forward PS of 1.02 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Nutex Health Inc. (NUTX) has a current P/OCF of 0.00. The 5-year average P/OCF is 1.49. The thresholds are as follows: Strongly Undervalued below -5.07, Undervalued between -5.07 and -1.79, Fairly Valued between 4.77 and -1.79, Overvalued between 4.77 and 8.05, and Strongly Overvalued above 8.05. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Nutex Health Inc. (NUTX) has a current P/FCF of 0.00. The 5-year average P/FCF is -88.96. The thresholds are as follows: Strongly Undervalued below -663.57, Undervalued between -663.57 and -376.27, Fairly Valued between 198.34 and -376.27, Overvalued between 198.34 and 485.65, and Strongly Overvalued above 485.65. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Nutex Health Inc (NUTX) has a current Price-to-Book (P/B) ratio of 3.23. Compared to its 3-year average P/B ratio of 2.95 , the current P/B ratio is approximately 9.27% higher. Relative to its 5-year average P/B ratio of 5.80, the current P/B ratio is about -44.34% higher. Nutex Health Inc (NUTX) has a Forward Free Cash Flow (FCF) yield of approximately 16.63%. Compared to its 3-year average FCF yield of 6.36%, the current FCF yield is approximately 161.48% lower. Relative to its 5-year average FCF yield of 6.20% , the current FCF yield is about 168.42% lower.
3.23
P/B
Median3y
2.95
Median5y
5.80
16.63
FCF Yield
Median3y
6.36
Median5y
6.20
Competitors Valuation Multiple
The average P/S ratio for NUTX's competitors is 1.13, providing a benchmark for relative valuation. Nutex Health Inc Corp (NUTX) exhibits a P/S ratio of 1.02, which is -9.77% above the industry average. Given its robust revenue growth of 239.87%, this premium appears sustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of NUTX increased by 273.90% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 1.30 to 8.24.
The secondary factor is the Revenue Growth, contributed 239.87%to the performance.
Overall, the performance of NUTX in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
Frequently Asked Questions
Is Nutex Health Inc (NUTX) currently overvalued or undervalued?
Nutex Health Inc (NUTX) is now in the Fair zone, suggesting that its current forward PS ratio of 1.02 is considered Fairly compared with the five-year average of -23.37. The fair price of Nutex Health Inc (NUTX) is between 127.09 to 198.26 according to relative valuation methord.
What is Nutex Health Inc (NUTX) fair value?
NUTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Nutex Health Inc (NUTX) is between 127.09 to 198.26 according to relative valuation methord.
How does NUTX's valuation metrics compare to the industry average?
The average P/S ratio for NUTX's competitors is 1.13, providing a benchmark for relative valuation. Nutex Health Inc Corp (NUTX) exhibits a P/S ratio of 1.02, which is -9.77% above the industry average. Given its robust revenue growth of 239.87%, this premium appears sustainable.
What is the current P/B ratio for Nutex Health Inc (NUTX) as of Jan 08 2026?
As of Jan 08 2026, Nutex Health Inc (NUTX) has a P/B ratio of 3.23. This indicates that the market values NUTX at 3.23 times its book value.
What is the current FCF Yield for Nutex Health Inc (NUTX) as of Jan 08 2026?
As of Jan 08 2026, Nutex Health Inc (NUTX) has a FCF Yield of 16.63%. This means that for every dollar of Nutex Health Inc’s market capitalization, the company generates 16.63 cents in free cash flow.
What is the current Forward P/E ratio for Nutex Health Inc (NUTX) as of Jan 08 2026?
As of Jan 08 2026, Nutex Health Inc (NUTX) has a Forward P/E ratio of 8.47. This means the market is willing to pay $8.47 for every dollar of Nutex Health Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Nutex Health Inc (NUTX) as of Jan 08 2026?
As of Jan 08 2026, Nutex Health Inc (NUTX) has a Forward P/S ratio of 1.02. This means the market is valuing NUTX at $1.02 for every dollar of expected revenue over the next 12 months.